CAJ | 학술논문

目的：探讨糖皮质激素（GC）对重症肌无力（MG）患者外周血白细胞介素-6（IL-6）和免疫球蛋白的影响。方法：治疗组为34例MG患者，采用GC治疗，疗程2个月，观察治疗前后临床症状改善情况及外周血IL-6和免疫球蛋白的水平。结果：经治疗2个月后，治疗组临床总有效率为82%（28/34）。治疗前MG患者血清IL-6、IgG1、IgG3均高于健康组，差异均有统计学意义（P<0.05）， IgM、IgA、IgG2、IgG4与健康组比较差异均无统计学意义（P>0.05）；经2个月治疗，血清IL-6、IgG1浓度降低，较治疗前差异有统计学意义（P<0.01）；IL-6与IgG1在治疗前及治疗后有正相关性，与IgG3无相关性。结论：GC可通过抑制MG患者体内IL-6和免疫球蛋白的产生，部分调节患者的免疫功能。
목적：탐토당피질격소（GC）대중증기무력（MG）환자외주혈백세포개소-6（IL-6）화면역구단백적영향。방법：치료조위34례MG환자，채용GC치료，료정2개월，관찰치료전후림상증상개선정황급외주혈IL-6화면역구단백적수평。결과：경치료2개월후，치료조림상총유효솔위82%（28/34）。치료전MG환자혈청IL-6、IgG1、IgG3균고우건강조，차이균유통계학의의（P<0.05）， IgM、IgA、IgG2、IgG4여건강조비교차이균무통계학의의（P>0.05）；경2개월치료，혈청IL-6、IgG1농도강저，교치료전차이유통계학의의（P<0.01）；IL-6여IgG1재치료전급치료후유정상관성，여IgG3무상관성。결론：GC가통과억제MG환자체내IL-6화면역구단백적산생，부분조절환자적면역공능。
To investigate the impact of glucocorticoid on IL-6 and immunoglobulin in patients with myasthenia gravis (MG). Methods: Thirty-four cases of MG in the treated group received glucocorticoid therapy for 2 months. Alterations in symptoms and peripheral blood levels of IL-6 and immunoglobulin were observed before and after treatment. The relationship between IL-6 and the others (IgG1,IgG3)of the patient were analyzed. Results: After two months of treatment,total effective rate in the treated group was 82%(28/34);serum levels of IL-6,IgG1 and IgG3 were higher in the MG groups than that in the healthy group(P<0 . 05). No statistical significance was noted in serum levels of IgM, IgA, IgG2 and IgG4 between the MG groups and the healthy group (P>0.05). After 2 months of treatment, significant differences was noted before and after treatment in IL-6 and IgG1 levels of the treated group(P<0.01). There was correlation between IL-6 and IgG1, but was not related to IgG3 before and after treatment in myasthenia gravis.Conclusion:Glucocorticoid can effectively regulate the function of both cellular and humoral immunity by decreasing the production of IL- 6 and immunoglobulin .